期刊文献+

HBsAg及HBVDNA定量水平在慢性乙型肝炎、肝硬化和肝癌患者中的变化 被引量:54

The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma
原文传递
导出
摘要 目的 了解HBsAg定量水平在慢性乙型肝炎、乙型肝炎肝硬化、HBsAg阳性的原发性肝癌患者中的变化及其在3组患者中与HBVDNA的相关性。方法采集47例慢性乙型肝炎患者(乙型肝炎组),72例乙型肝炎肝硬化患者(肝硬化组)及54例肝癌患者(肝癌组)的血清标本,用雅培化学发光法进行HBsAg定量测定,荧光PCR定量法检测HBVDNA量水平。多组分析采用KruskalWallis检验,两组间比较采用Mann-WhitneyU检验,相关胜分析采用Spearman检验。结果HBsAg定量值在乙型肝炎、肝硬化、肝癌组患者中的中位数分别为2361.10、1001.64、594.35IU/nfl,3组间呈逐渐下降趋势,X^2=24.394,P〈0.05,差异有统计学意义;乙型肝炎组与肝硬化组比较,z=-3.754,P〈0.05,差异有统计学意义;乙型肝炎组与肝癌组比较,Z=-4.630,P〈0.05,差异有统计学意义;而肝硬化组与肝癌组比较,差异无统计学意义。HBeAg阳性患者,HBsAg定量值在乙型肝炎组、肝硬化组、肝癌组患者的中位数分别为3259.83、1077.30、789.72IU/ml,3组间呈下降趋势,x^2=15.643,P〈0.01,差异有统计学意义。对于HBeAg阴性患者,HBsAg定量值在乙型肝炎组、肝硬化组、肝癌组患者的中位数分别为1669.00、1001.64、582.05IU/ml,3组间呈下降趋势,x^2=6.423,P〈0.05,差异有统计学意义。HBVDNA定量值在乙型肝炎组、肝硬化组、肝癌组患者的中位数分别为5.3579、4.2207、1.0000log10拷贝/ml,4分位数间距分别为(4.3579~6.8745)、(0.0000~5.7393)、(0.0000~4.6651)log10拷贝/ml,3组HBVDNA定量值比较,x^2=31.412,P〈0.05,差异有统计学意义;HBsAg与HBVDNA在乙型肝炎组(r=0.297,P〈0.05)、肝硬化组(r=0.346,P〈0.05)、肝癌组(r=0.452,P〈0.05)均呈正相关。结论HBsAg定量值在慢性乙型肝炎、肝硬化、肝癌患者中逐渐降低,且与HBVDNA水平正相关。 Objective To investigate the discrepancy ofHBsAg titre and correlation ofHBV DNA levels among patients with chronic hepatitis B (CHB), HBV-related liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Methods tlBsAg titre and ttBV DNA in serum samples were measured among 47 CHB, 72 LC and 54 HCC cases using Abbott chemiluminescence and fluorescence quantitative PCR, respectively. Statistical analyses among multiple groups, between two groups and about the correlation were pertormed using Kruskal-Wallis test, Mann-Whimey U test and Spearman test, respectively. Results The median HBsAg titre level in serum samples decreased from 2361.10 IU/ml in CHB cohort to 1001.64 IU/ml in LC cohort and 594.35 IU/ml in HCC cohort, suggesting a statistically significant difference (x2 = 24.394,P 〈 0.05). Moreover, HBsAg titre in CHB group was significantly higher than that in LC group (Z = -3.754, P 〈 0.05). CHB patients had significantly higher HBsAg titre than HCC cases (Z = -4.630,P 〈 0.05). However, there was no statistically significant difference in HBsAg titre between LC and HCC group. Among HBeAg positive patients, HBsAg titre decreased from 3259.83 IU/ml in CHB group to 1077.30 IU/ml in LC group and 789.72 1U/ml in HCC group, indicating a significant difference (x2 = 15.643, P 〈 0.01). Among HBeAg negative patients, HBsAg titre declined from 1669.00 IU/ml in CHB group to 1001.64 1U/ml in LC group and 582.05 IU/ml in HCC group, suggesting of a significant difference (x2 = 6.423, P 〈 0.05). Positive correlation between HBsAg titre and HBV DNA was found in CHB (r = 0.297, P 〈 0.05), LC(r = 0.346, P 〈 0.05) and HCC(r = 0.452, P 〈 0.05), respectively. Conclusion HBsAg titre level in serum decreased progressively from CI-IB to LC and HCC group. There were positive correlations between HBsAg titre and HBV DNA level in CHB, LC and HCC.
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2011年第10期743-746,共4页 Chinese Journal of Hepatology
基金 国家重点基础研究发展规划基金资助项目(2007CB512801) “十一五”科技重大专项(2008ZX10002-005) 天津市卫生局重点攻关资助项目(07KG9)
关键词 肝炎抗原 乙型 肝炎病毒 乙型 肝炎 乙型 慢胜 肝硬化 肝细胞癌 Hepatitis B antigens Hepatitis B virus Hepatitis B,chronic Liver cirrhosis Hepatocellular carcinoma
  • 相关文献

参考文献11

  • 1Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med, 2004, 350: 1118-1129.
  • 2中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1957
  • 3原发性肝癌的临床诊断与分期标准[J].肝脏,2004,9(S1):67-68. 被引量:53
  • 4Ismail N, Fish GE, Smith MB. Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus. J Clin Microbiol, 2004, 42:610-617.
  • 5Wong DK, Yuen MF, Poon RT, et al. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol, 2006, 45: 553-559.
  • 6Thompson AJ, Nguyen T, Iser D, et al. Senlm hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology, 2010, 51: 1933-1944.
  • 7Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B vires (HBV)-infection: a European perspective. J Hepatol, 2010, 52: 514-522.
  • 8Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol, 2010, 52:508-513.
  • 9Galli C, Orlandini E, Penzo L, et al. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology? J Med Virol, 2008, 80: 974-999.
  • 10Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006, 44: 675-684.

二级参考文献15

共引文献2008

同被引文献467

引证文献54

二级引证文献324

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部